Standout Papers

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer 2011 2026 2016 2021 1.7k
  1. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  2. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (2015)
    Sandra M. Swain, José Baselga et al. New England Journal of Medicine
  3. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer (2015)
    Martin Schlumberger, Makoto Tahara et al. New England Journal of Medicine
  4. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial (2019)
    Ken Kato, Byoung Chul Cho et al. The Lancet Oncology
  5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study (2013)
    Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology
  6. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial (2014)
    Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology
  7. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial (2017)
    Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology
  8. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus (2018)
    Manish A. Shah, Takashi Kojima et al. JAMA Oncology
  9. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial (2020)
    Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology

Immediate Impact

8 by Nobel laureates 9 from Science/Nature 103 standout
Sub-graph 1 of 18

Citing Papers

Oesophageal cancer
2024 Standout
Thyroid Cancer
2024 Standout
4 intermediate papers

Works of Sung‐Bae Kim being referenced

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
2019 Standout
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Sung‐Bae Kim 9820 5196 3052 3393 425 16.4k
Se‐Hoon Lee 8820 8462 1739 1584 584 16.7k
Sabino De Placido 7699 4412 1195 1608 376 13.7k
Daniele Santini 8608 4055 2493 1296 608 14.8k
Patrick Schöffski 9407 9276 3130 618 500 18.9k
Jordan Berlin 15107 6177 3357 1600 351 22.4k
Gerardo Botti 6523 2100 1911 1009 538 14.5k
Masakazu Toi 10580 5860 1363 2170 651 20.9k
Hye Seung Lee 5814 4930 5416 823 449 15.7k
Keunchil Park 17565 16632 2605 1758 564 26.7k
Chris Verslype 7097 3724 3715 1095 332 15.0k

All Works

Loading papers...

Rankless by CCL
2026